The influence of antipsychotic medication on dopamine D2 receptor availability. A [11C] raclopride PET study

Recruiting

• Conditions: 10039628; dopamine; psychosis

• Registration Number: NL-OMON55703
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

* The participant understands the study and is able to provide written informed
consent
* Must be between the ages of 18-60
* Sufficient command of the Dutch language
* Must have a diagnosis of schizophrenia, schizoaffective disorder,
schizophreniform disorder, or those classified as Other Specified Schizophrenia
Spectrum and Other Psychotic Disorder
* Be mentally competent, as determined by their treating physician
* The participant has had a first episode of psychosis and uses antipsychotic
medication at the start of the HAMLETT study
* The participant is about to discontinue antipsychotic medication
* Psychotic symptoms are in remission for 3-6 months
* HAMLETT is the only medical-scientific medication study in which the patient
participates

Exclusion Criteria

* Presence of a neurological disorder
* Visual or hearing problems that cannot be corrected
* Participation in a scientific research study during the past year involving
radiation
* the refusal to be informed (by notifying the participant*s physician) of
structural brain abnormalities that could be detected during the experiment
* MR incompatible implants in the body
* Risk of having metal particles in the eyes
* Tattoo*s containing red pigments that form a safety risk
* Alcohol or substance abuse in the past 6 months
* Insufficient knowledge of the Dutch language
* Inability to undergo cognitive testing
* Use of antipsychotic medication
* dangerous or harmful behaviour (i.e. behaviour with a risk of severe physical
injury, or actual physical injury inflicted, to self or others) occurred during
the psychosis
* Coercive treatment (based on a judicial ruling)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is be the binding potential of [11C]raclopride in the<br /><br>striatum (caudate and putamen).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>